Colorectal Cancer

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Denalee O'Malley, PhD, sheds light on racial and ethnic disparities in colorectal cancer screening, and strategies that can be used to address existing barriers in the clinic and beyond.

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

Following in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.

Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.

Mike Cusnir, MD, discusses the most effective uses of chemotherapy in colorectal cancer.

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer, and early results have established the pathway as a prime target for drug development.

Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.

Rohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.

Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.

Temozolomide priming followed by the combination of low-dose ipilimumab and nivolumab may produce durable clinical benefit in microsatellite stable and MGMT-silenced metastatic colorectal cancer.

Afsaneh Barzi, MD, PhD, discusses the safety and efficacy of regorafenib in combination with pembrolizumab in patients with MSS colorectal cancer and describes potential next steps for further exploration of novel combinations in this population.

The Ministry of Health, Labour, and Welfare has approved Guardant360 CDx to perform comprehensive genomic profiling in patients with advanced solid cancers.

Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.

Rohan Jeyarajah, MD, discusses the potential role of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in colorectal cancer with liver metastases.

David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.